Skip to content
Ocular Toxicokinetic (TK) Models
Ichor Life Sciences provide precise data on ocular drug absorption, distribution, metabolism, and elimination. Support your preclinical ophthalmic studies with validated in vivo models for drug safety and efficacy assessment.
Ichor Life Sciences has specialized in ophthalmic pharmacology for over 10 years. Our expert ophthalmology team combined with our expertise in sample collection makes us a trusted ocular PK/TK partner for your team! Let our experienced in vivo and bioanalytical teams help guide your formulation optimization and dose selection.
Dose Administration Techniques
Our team is experienced in a wide range of ocular and systemic administration routes to support both ocular pharmacokinetic and biodistribution studies. Depending on your program’s needs, we can tailor the route of administration to achieve optimal exposure.
- Intravitreal
- Subretinal
- Intracameral
- Suprachoroidal
- Topical
- Intravenous
- Intraperitoneal
- Subcutaneous
Sample Collection - Blood
Comprehensive blood sampling techniques are available to support time-course PK/TK analyses. The selection of the technique depends on species, sample volume requirements, and study design.
- Cardiac puncture
- Vena cava
- Tail vein
- Jugular vein
- Marginal ear vein (rabbit)
- Submandibular vein
- Saphenous vein
Sample Collection – Ocular Tissues
Tissue-level quantification supports detailed biodistribution and compartmental analysis. Dissected ocular structures can be analyzed individually or pooled depending on your study needs.
- Cornea
- Conjunctiva
- Sclera
- Iris – Ciliary body
- Lens
- Retina/RPE/Choroid
- Optic Nerve
Sample Collection - Ocular/Other
Our team routinely collects a variety of ocular fluids and glands to evaluate local exposure.
- Aqueous Humor
- Vitreous Humor
- Lacrimal Gland
- Harderian Gland
- Tear Fluid
Core Capabilities and Services
Featured Models
We offer a diverse range of preclinical ocular models designed to evaluate pharmacokinetics, pharmacodynamics, and therapeutic efficacy across a variety of disease indications. These models enable precise characterization of drug performance to help support the development of your compound.
Retinal Degeneration & Atrophy: We provide multiple models of inherited or acquired retinal degeneration to assess photoreceptor loss, retinal pigment epithelium damage, and functional decline.
- ABCA4-/- Mouse Model
- Blue Light Illumination Stargardt’s Model
- Sodium Iodate Induced Geographic Atrophy
Neovascular and Ischemic Retinopathy: These models replicate key mechanisms of retinal neovascularization and ischemic injury, allowing evaluation of anti-angiogenic and neuroprotective therapies.
- Laser-Induced Choroidal Neovascularization
- Retinal Ischemia-Reperfusion Injury
Glaucoma and Optic Neuropathy: These models facilitate assessment of retinal ganglion cell survival, axonal integrity, and IOP-modulating compounds.
- Laser-Induced Ocular Hypertension
- Optic Nerve Crush
Ocular Surface Inflammation: Inflammatory and dry eye models allow for detailed investigation of surface pathology, tear film stability, and local cytokine responses.
- Scopolamine-Induced Dry Eye
- LPS-Induced Uveitis
Study Design Options
| Study Design Option | Description |
|---|---|
| Single-dose PK (Systemic or Local Administration) | Characterization of absorption, distribution, metabolism, and elimination following a single administration. These studies are ideal for early screening and establishing your initial exposure profiles. |
| Repeat-Dose or Steady-State PK | Evaluation of compound accumulation, clearance, and exposure consistency over multiple doses or chronic regimens. These studies support dose regimen scheduling and long-term exposure assessment. |
| Ocular Biodistribution | These studies support quantification of compound concentrations across ocular tissues and fluids to determine tissue-specific penetration and retention. |
| Comparative Route or Formulation Bridging Studies | Head-to-head evaluation of different delivery routes or formulations to identify optimal strategies for ocular exposure and systemic tolerability. |
| Coordinated Plasma-Ocular PK Correlation | These integrated studies assess plasma and ocular concentrations at the same timepoints to establish systemic-ocular exposure relationships and inform translational modeling. |